Surrogate end points in heart failure trials.
Gheorghiade
Mihai
M
Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA. m-gheorghiade@northwestern.edu
Adams
Kirkwood F
KF
Gattis
Wendy A
WA
Teerlink
John R
JR
Orlandi
Cesare
C
O'Connor
Christopher M
CM
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000401:mortality; D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D017079:Exercise Tolerance / Q000187:drug effects / Q000502:physiology; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000401:mortality* / Q000503:physiopathology; D006801:Humans; D018377:Neurotransmitter Agents / Q000037:antagonists & inhibitors* / Q000097:blood; D009638:Norepinephrine / Q000097:blood; D013318:Stroke Volume / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use; D016277:Ventricular Function, Left / Q000187:drug effects* / Q000502:physiology; D020257:Ventricular Remodeling / Q000187:drug effects / Q000502:physiology
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D015415:Biomarkers; D018377:Neurotransmitter Agents; D014665:Vasodilator Agents; D009638:Norepinephrine